Docoh
Loading...

AVTX Avalo Therapeutics

News

From Benzinga Pro
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
18 Jan 22
Pre-Market Outlook, Markets, Movers
5 Penny Stocks Insiders Are Buying
18 Jan 22
Long Ideas, News, Penny Stocks, Small Cap, Insider Trades, Pre-Market Outlook, Markets, Trading Ideas
When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and traders interested in penny stocks can consider this a factor in their overall investment or trading decision.
3 Penny Stocks Insiders Are Buying
12 Jan 22
Long Ideas, News, Penny Stocks, Insider Trades, Pre-Market Outlook, Markets, Trading Ideas
When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and traders interested in penny stocks can consider this a factor in their overall investment or trading decision.
56 Biggest Movers From Friday
10 Jan 22
News, Penny Stocks, Small Cap, Pre-Market Outlook, Markets, Movers, Trading Ideas
Gainers Hour Loop, Inc. (NASDAQ: HOUR) shares jumped 99.8% to $7.99 after the company priced its IPO at $4 per share.
12 Health Care Stocks Moving In Friday's Intraday Session
7 Jan 22
Intraday Update, Markets, Movers
Stocks That Hit 52-Week Lows On Friday
7 Jan 22
News, Options, Intraday Update, Markets, Movers, Trading Ideas
Before 10 am on Friday, 110 companies set new 52-week lows.
58 Biggest Movers From Yesterday
7 Jan 22
News, Penny Stocks, Small Cap, Pre-Market Outlook, Markets, Movers, Trading Ideas
Gainers Eargo, Inc. (NASDAQ: EAR) shares climbed 59.7% to close at $7.28 on Thurs after the company announced the Department of Justice confirmed to it that the previously-announced criminal probe is no long active.
12 Health Care Stocks Moving In Thursday's Intraday Session
6 Jan 22
Intraday Update, Markets, Movers
Stocks That Hit 52-Week Lows On Thursday
6 Jan 22
News, Options, Intraday Update, Markets, Movers, Trading Ideas
On Thursday, 615 stocks hit new 52-week lows.
The Daily Biotech Pulse: Lilly Strikes Neurological R&D Collaboration, Valneva Confirms Vaccine Timelines, Biohaven Gains On Strong Migraine Drug Sales
6 Jan 22
Biotech, Earnings, News, Penny Stocks, Guidance, Offerings, Small Cap, FDA, General
Here's a roundup of top developments in the biotech space over the last 24 hours:
Avalo To Highlight Phase 1b Results For AVTX-002And Presents Additional Program Updates At Today's 2022 Investor Event
6 Jan 22
Biotech, General
Immunology portfolio highlighted by success of a second positive study with AVTX-002 further validates the LIGHT mechanism of action in inflammatory diseases Efficacy signal demonstrated in heavily pre-treated
The Week Ahead In Biotech (Jan 2-Jan. 8): Stray Clinical Readouts In Focus In Slow News Week
2 Jan 22
Biotech, Earnings, News, Penny Stocks, Small Cap, FDA, General
Biotech stocks came under selling pressure in the final week of 2021, although they carved out modest gains for the year.
The Week Ahead In Biotech (Dec.26-Jan. 1): Xeris FDA Decision, Pending Clinical Readouts In Focus In Final Week Of Year
26 Dec 21
Biotech, News, Penny Stocks, Small Cap, FDA, General
Biopharma stocks eked out modest gains in the week ending Dec. 23, with regulatory decisions, clinical readouts and COVID-19 treatment and vaccine developments dictating sentiment.
Avalo Therapeutics Appoints Steven J. Boyd As Chairman Of Board
15 Dec 21
News, Management
On December 14, 2021, the board of directors (the “Board”) of Avalo Therapeutics, Inc. (the “Company”) appointed Steven J. Boyd, a current non-employee director of the Board, as Chairman of the
4 Penny Stocks Insiders Are Buying
15 Dec 21
Long Ideas, News, Penny Stocks, Insider Trades, Pre-Market Outlook, Markets, Trading Ideas
When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and traders interested in penny stocks can consider this a factor in their overall investment or trading decision.
Avalo Therapeutics Q3 EPS $(0.17) Down From $(0.16) YoY, Sales $1.35M Up From $1.11M YoY
9 Nov 21
Earnings, News
Avalo Therapeutics (NASDAQ:AVTX) reported quarterly losses of $(0.17) per share. This is a 6.25 percent decrease over losses of $(0.16) per share from the same period last year. The company reported $1.35 million in

Press releases

From Benzinga Pro
Thinking about buying stock in Avalo Therapeutics, AxoGen, Ocugen, BioNano Genomics, or Aurora Innovation?
12 Jan 22
Opinion, Press Releases
NEW YORK, Jan. 12, 2022 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for AVTX, AXGN, OCGN, BNGO, and AUR.
Avalo Therapeutics Appoints Stephen Smolinski as Chief Commercial Officer
10 Jan 22
News, Management, Markets, Press Releases
WAYNE, Pa. and ROCKVILLE, Md., Jan. 10, 2022 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (NASDAQ:AVTX) ("Avalo" or the "Company"), a leading clinical-stage precision medicine company that discovers, develops, and
Avalo Reports Positive Phase 1b Results for AVTX-002 in Moderate to Severe Crohn's Disease Patients and Presents Additional Program Updates at 2022 Investor Event
6 Jan 22
News, Health Care, Press Releases
Immunology portfolio highlighted by success of a second positive study with AVTX-002 further validates the LIGHT mechanism of action in inflammatory diseasesEfficacy signal demonstrated in heavily pre-treated subjects
Avalo Therapeutics to Host Virtual Investor Day on January 6, 2022
16 Dec 21
News, Press Releases
WAYNE, Pa. and ROCKVILLE, Md., Dec. 16, 2021 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (NASDAQ:AVTX), a leading clinical-stage precision medicine company that discovers, develops, and commercializes targeted
Avalo Appoints Two New Independent Directors to Its Board
6 Dec 21
News, Management, Press Releases
WAYNE, Pa. and ROCKVILLE, Md., Dec. 06, 2021 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (NASDAQ:AVTX), a leading clinical-stage precision medicine company that discovers, develops, and commercializes targeted
Avalo to Present at Two Upcoming Conferences
11 Nov 21
News, Press Releases
WAYNE, Pa. and ROCKVILLE, Md., Nov. 11, 2021 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (NASDAQ:AVTX), a leading clinical-stage precision medicine company that discovers, develops, and commercializes targeted
Avalo Reports Third Quarter 2021 Financial Results and Provides Business Updates
9 Nov 21
Earnings, Press Releases
Topline Phase 1b data for AVTX-002 in moderate to severe Crohn's disease patients expected in the fourth quarter of 2021Multiple data readouts across programs anticipated within the next six monthsCash and cash